Why is RareCan interested in Pseudomyxoma Peritonei (PMP)?
RareCan is working to accelerate research into Pseudomyxoma Peritonei by making it easier for researchers to connect with people who have this rare condition. You can help us do this by becoming a RareCan member and sharing information with us about your diagnosis. We will then get in touch with you about any research opportunities that might be suitable for you.
RARECAN ALREADY HAS
What is Pseudomyxoma Peritonei (PMP)?
Pseudomyxoma Peritonei is a condition that starts in the appendix (usually) and affects the peritoneum, a layer of tissue which lines the inside of the abdomen.
How rare is Pseudomyxoma Peritonei?
PMP occurs in approximately 3.2 people per million.
Who does Pseudomyxoma Peritonei affect?
PMP is can affect people at any age but it is more common in adults. It is slightly more common in women than it is in men.
Pseudomyxoma Peritonei in other parts of the body
PMP usually starts in the appendix but it can also start in other parts of the body, such as the bowel, the bladder or the ovaries, although this is rare.
If you have Pseudomyxoma Peritonei (PMP) and are looking for support, we recommend the following website:
Opportunities for Members with Pseudomyxoma Peritonei
The RareCan BioResource
Donating your samples for medical research
Joining RareCan gives you the ability to donate your tissue samples to the BioResource for medical research. Please note that signing up to RareCan does not commit you to donating tissue and you can cancel your membership at any time. If you have Pseudomyxoma Peritonei and would like to find out more, please click the button below.
I have a cancer diagnosis
If you have a cancer diagnosis or you are the parent of a child with a cancer diagnosis, please start here.
I'm a supporter
If you’re a friend or family member of someone with cancer, a nurse, an oncologist, an activist, a fundraiser or you’d simply like to help, please start here.
I'm a researcher
If you are interested in setting up a research project or clinical trial aimed at improving the care people affected by rare cancer receive please start here.